Exact Mass: 328.1787
Exact Mass Matches: 328.1787
Found 160 metabolites which its exact mass value is equals to given mass value 328.1787,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Labetalol
Labetalol is only found in individuals that have used or taken this drug. It is a blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive (PubChem). Labetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity. CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7134; ORIGINAL_PRECURSOR_SCAN_NO 7131 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7100; ORIGINAL_PRECURSOR_SCAN_NO 7098 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7094; ORIGINAL_PRECURSOR_SCAN_NO 7091 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7132; ORIGINAL_PRECURSOR_SCAN_NO 7130 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3398; ORIGINAL_PRECURSOR_SCAN_NO 3397 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3392; ORIGINAL_PRECURSOR_SCAN_NO 3391 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3400; ORIGINAL_PRECURSOR_SCAN_NO 3399 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7150; ORIGINAL_PRECURSOR_SCAN_NO 7149 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3395; ORIGINAL_PRECURSOR_SCAN_NO 3393 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3466; ORIGINAL_PRECURSOR_SCAN_NO 3465 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3405; ORIGINAL_PRECURSOR_SCAN_NO 3404 CONFIDENCE standard compound; INTERNAL_ID 220; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7142; ORIGINAL_PRECURSOR_SCAN_NO 7140 C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AG - Alpha and beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents CONFIDENCE standard compound; INTERNAL_ID 2757 CONFIDENCE standard compound; INTERNAL_ID 8188 Labetalol (AH5158) is an orally active selective α1- and non-selective β-adrenergic receptors competitive antagonist. Labetalol, an anti-hypertensive agent, can be used for the research of cardiovascular disease, such as hypertension in pregnancy[1][2][3].
GELSEDINE
Glycylprolylarginine
Benzamide, 3-(3-((2-(3,4-dihydroxyphenyl)ethyl)amino)butyl)-
1beta,10beta(8,12)-diepoxy-7beta,11beta-dihydroxy-8beta,12alpha-dimethoxyeremophilane
(3S,6R,9S,10R)-9-hydroxy-3-methyl-2,4-dioxo-10-pentyloxecan-6-yl acetate|cytospolide P
3beta-acetoxy-5alpha,11,12,13-tetrahydroxy-eudesm-4(15)-ene|3??-Acetoxy,5??,11,12,13-tetrahydroxy-eudesm-4(15)-ene
10-Hydroxydihydroperaksine
labetalol
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AG - Alpha and beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Labetalol (AH5158) is an orally active selective α1- and non-selective β-adrenergic receptors competitive antagonist. Labetalol, an anti-hypertensive agent, can be used for the research of cardiovascular disease, such as hypertension in pregnancy[1][2][3].
(2S)-2-[(1S)-1-carboxyundecyl]-5-oxooxolane-2-carboxylic acid
(2S)-2-[(1S)-1-carboxyundecyl]-5-oxotetrahydrofuran-2-carboxylic acid
(2S)-2-[(1S)-1-carboxyundecyl]-5-oxotetrahydrofuran-2-carboxylic acid_major
Ala Ala Ala Pro
Ala Ala Pro Ala
Ala Pro Ala Ala
Gly Gly Pro Val
Gly Gly Val Pro
Gly Pro Gly Val
Gly Pro Val Gly
Gly Val Gly Pro
Gly Val Pro Gly
Pro Ala Ala Ala
Pro Gly Gly Val
Pro Gly Val Gly
Pro Val Gly Gly
Val Gly Gly Pro
Val Gly Pro Gly
Val Pro Gly Gly
4-((2-(4-AMINOPHENOXY)ETHYL)(BENZYL)AMINO)BUTANOIC ACID
Acrylic acid, butyl acrylate, isobutyl acrylate polymer
N-(3-Boc-Aminomethylphenyl)-n-(4-methoxyphenyl)amine
2-Methyl-6-phenyl-N-(2-phenylethyl)-5H-pyrrolo(3,2-d)pyrimidin-4-amine
2-METHYL-1-(3-MORPHOLINOPROPYL)-5-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID
3,5-DI-TERT-BUTYL-4-HYDROXYBENZYLPHOSPHONIC ACID MONOETHYL ESTER
Serdemetan
C274 - Antineoplastic Agent > C129839 - Apoptotic Pathway-targeting Antineoplastic Agent D011838 - Radiation-Sensitizing Agents Serdemetan (JNJ-26854165) is a potent anticancer agent with radiosensitizing activity. Serdemetan exhibits antiproliferative activity in various p53 wild-type tumor cells. Serdemetan also antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes[1][2][3].
N-((1H-benzo[d][1,2,3]triazol-1-yl)Methyl)-N-benzyl-1-phenylmethanamine
DILEVALOL
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
2-methoxy-N-[[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl]methyl]ethanamine
5-[3-(Dimethylamino)-2-methylpropyl]-5H-dibenz[b,f]azepine hydrochloride
(R*,S*)-(1)-5-(1-Hydroxy-2-((1-methyl-3-phenylpropyl)amino)ethyl)salicylamide
5-(5-(4-(5-Hydro-4-methyl-2-oxazolyl)phenoxy)pentyl)-3-methyl isoxazole
(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[(E,4R,5S)-5-hydroxy-4-methylhex-2-enyl]oxan-2-yl]-3-methylbut-2-enoic acid
[3-Carboxy-2-(6-carboxy-3,4-dimethylidenehexanoyl)oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,7E)-8-carboxyocta-4,7-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(3E,7E)-8-carboxyocta-3,7-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(4E,6E)-8-carboxyocta-4,6-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(2E,7E)-8-carboxyocta-2,7-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(3E,6E)-8-carboxyocta-3,6-dienoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(5E,7E)-8-carboxyocta-5,7-dienoyl]oxypropyl]-trimethylazanium
4-Cyclohexanecarbonyl-1-(2-phenylethyl)piperazine-2,6-dione
N-[(E)-Benzylideneamino]-6-methyl-2-phenyl-5-prop-2-enylpyrimidin-4-amine
2-Hydroxy-5-((1S)-1-hydroxy-2-(((1S)-1-methyl-3-phenylpropyl)amino)ethyl)benzamide
Val-Asn-Pro
A tripeptide composed of L-valine, L-asparagine, and L-proline joined by peptide linkages.
N-[3-(N-ethylanilino)propyl]-2,4-dimethyl-6-oxo-3-pyrancarboxamide
1-Tert-butyl-5-[(4-fluoro-2,6-dimethylphenyl)methyl]-4-pyrazolo[3,4-d]pyrimidinone
N1-[2-(1H-indol-3-yl)ethyl]-N3-pyridin-4-ylbenzene-1,3-diamine
1-[(2,2-dimethyl-3H-benzofuran-7-yl)oxy]-3-(2-pyridinylmethylamino)-2-propanol
3-Methyl-5-[5-[4-(4-methyl-4,5-dihydrooxazol-2-yl)phenoxy]pentyl]isoxazole
(2s)-5-[(2r,3s,6e,8r,9r)-3,8-dihydroxy-9-methyl-10-oxo-2,3,4,5,8,9-hexahydrooxecin-2-yl]pentan-2-yl acetate
(3z)-3-{2-[(3s,4z)-3-ethyl-3-hydroxy-1-methylpiperidin-4-ylidene]ethylidene}-7-methoxyindol-2-ol
(1s,10s)-24-methyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-2,4,6,8,11(21),13,15,17-octaene
(1s,12as,13r,14r,15ar)-14-chloro-1-ethyl-13-hydroxy-1h,4h,5h,6h,7h,8h,9h,10h,12ah,13h,14h,15h,15ah-cyclopenta[c]oxacyclotetradecan-3-one
24-methyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-2,4,6,8,11(21),13,15,17-octaene
9-hydroxy-10-(4-hydroxypentyl)-3-methyl-2-oxo-3,4,7,8,9,10-hexahydrooxecin-4-yl acetate
1-myrtenol
{"Ingredient_id": "HBIN002821","Ingredient_name": "1-myrtenol","Alias": "NA","Ingredient_formula": "C24H24O","Ingredient_Smile": "CC1(C2CC=C(C1C2)C(C3=C4C=CC=CC4=CC5=CC=CC=C53)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "33352","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3β-acetoxy,5α,11,12,13-tetrahydroxy-eudesm-4(15)-ene
{"Ingredient_id": "HBIN008147","Ingredient_name": "3\u03b2-acetoxy,5\u03b1,11,12,13-tetrahydroxy-eudesm-4(15)-ene","Alias": "NA","Ingredient_formula": "C17H28O6","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "287","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
